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was higher for open procedures (90 [4.85%] open versus 743 [0.67%] laparoscopic; 
p< 0.001). Independent risk factors for SSI included acute cholecystitis (odds ratio 
[OR], 1.53; 95% confidence interval [CI], 1.32–1.77), choledocholithiasis (OR, 1.44; 
95% CI, 1.10–1.88), open approach (OR, 5.51; 95% CI, 4.00–7.61) laparoscopic con-
verted to open approach (OR, 5.48; 95% CI, 3.99–7.54), and concurrent bile duct 
repair (OR, 4.76; 95% CI, 1.93–11.70). Females had significantly decreased risk of SSI 
(OR, 0.75; 95% CI, 0.65–0.88). ConClusions: Acute cholecystitis, choledocholithi-
asis, and concurrent bile duct repair were associated with increased risk of SSI 
after cholecystectomy, controlling for open surgery, age, and gender. Our findings 
suggest that stratification of SSI rates by these operative factors is important when 
comparing rates between facilities.
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objeCtives: Describe the prevalence of contraindications to chronic hepatitis C 
(CHC) treatment among CHC patients not receiving CHC treatment (direct-acting 
antiviral [DAA] protease inhibitors, peg-interferon alpha, or ribavirin). Methods: 
Adult patients with ≥ 2 CHC diagnoses (ICD-9-CM codes 070.44, 070.54, 070.70, 
070.71) and no DAA fills at any time in their claims history were selected from a 
de-identified US-based claims database (2010-2012); the first CHC diagnosis after 
5/13/2011 was defined as the index date. Patients with CHC treatment 6-months 
before or 12 months after the index date were excluded. All patients were required 
to have continuous eligibility and no claims for hepatitis B during the 6-months 
before (baseline) and 12-months after their index dates. Contraindications (based 
on a World Health Organization hepatitis C guide) during the baseline period were 
identified based on ICD-9 codes and described for the overall cohort as well as 
stratified by age (18-39; 40-49; 50-59; 60-69; 70-79; 80+). Results: There were 12,726 
untreated patients identified, of which 7,644 (60.1%) had ≥ 1 baseline contraindica-
tion to peg-interferon or ribavirin. Untreated patients were 56 years old on average 
and more often male (61%). Approximately 86.8% of the untreated cohort had no 
claim for any CHC treatment any time in their claims history. The most common 
contraindications included arterial hypertension (32.1%), hepatic decompensation 
(22.3%), major system impairment (19.2%), and psychiatric depression (11.0%). Age-
stratified results showed increasing prevalence of contraindications with age; rates 
of contraindications increased from 44.2% among patients 18-39 to 76.65% among 
patients 80 years old and older. ConClusions: A high proportion of untreated CHC 
patients had diagnoses for contraindicated conditions, and the prevalence of these 
contraindications increased with age.
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objeCtives: Acute pancreatitis (AP) is associated with significant morbidity and 
mortality, representing a severe economic burden for health care system. Numerous 
attempts were made to find medications able to inhibit secretion of pancreatic 
enzymes and/or inflammatory cytokines in patients with AP to prevent further 
destruction of pancreas. There exist some evidences demonstrating that a cyclooxy-
genase inhibitor lornoxicam may inhibit secretion of inflammatory cytokines. The 
objective of the study was to investigate if lornoxicam administration might be clini-
cally and economically beneficial in patients with AP. Methods: Patients with AP 
were admitted in a Moscow hospital in 2010-2011. All of them were treated according 
to existing Russian standards of AP treatment. Part of patients were administered 
with lornoxicam iv bid during the first 5 days of hospitalization (16-32 mg a day). 
The information on the patients was collected using electronic health records (EHR) 
and then analyzed. Due to differences in baseline characteristics of the groups 
of patients treated and non-treated with lornoxicam, propensity scores matching 
technique was used. Logistic regression model was built to calculate propensity to 
be treated with lornoxicam for each patient. Then mortality rates were compared for 
the matched cohorts treated and non-treated with lornoxicam. Finally, the cost of 
one prevented death was calculated. Results: Totally 264 patients were identified 
in EHR, lornoxicame was administered to 74 patients. Propensity scores adjusted 
mortality rate was 6.0% for lornoxicam group and 20.0% for control group (p= 0.037). 
Thus, administration of lornoxicam might prevent mortality in 14% patients with AP. 
The cost of the 5-day course of lornoxicam was 2,602 RUB (78 USD). Therefore, the 
cost of one prevented death due to AP was 18,586 RUB (556 USD). ConClusions: 
It was demonstrated that intravenous injections of lornoxicam in patients with AP 
was not only potentially life-saving, but also cost effective, given the low cost of 
one prevented death.
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objeCtives: To determine the Prevalence and risk factors of Hepatitis B & C 
among the Barbers and their regular shaving clients in the Hyderabad Barber 
Shops of Pakistan. Methods: A cross sectional study was conducted to deter-
mine the sero-prevalence of Hepatitis-B virus (HBV) and Hepatitis-C virus (HCV) 
among barbers and their clients in Hyderabad Sindh Pakistan and to assess their 
knowledge, attitude and practices regarding these two viruses and their mode of 
transmission. Sampling was done by using a-2-stage sampling techniques. A close 
Collaboration between stakeholders underpinned by dynamic information exchange 
is the prerequisite of a systems-based market. If other industry sectors such as 
consumer goods, finance and telecommunications serve as a model for systems-
thinking, we will expect novel linkages between health care stakeholders to become 
more prevalent as population health goals unifies incentives. While many acknowl-
edge the need to move toward a more integrated “systems thinking” approach – one 
that maps influence patterns, amplifies interdependencies, and drives collective 
outcomes, they struggle with actual implementation. A recent survey of close to 
300 Biopharma executives, EU and US Payers, and US providers reveals insight 
into their needs, their disparate perceptions, and their levels of confidence in the 
ability to shift to a systems-thinking collaborative culture. Approximately 25% of 
respondents stated they were not aligned with other stakeholders, though agree 
they need better alignment and foresee closer collaboration in the future. More 
than 70% of stakeholders believe data transparency and information-sharing is 
critically important to a successful and interoperable health care system, yet very 
few from each group were willing to demonstrate such transparency. Most health 
care industry stakeholders are ill prepared for the necessary trust-building activi-
ties required by this anticipated transition. A viable and sustainable information 
network provides the structure, aligned incentives and competitive collaboration the 
bricks and mortar, and trust the cornerstone. Until they can build that and foster a 
culture of transparency, they won’t achieve the cost and innovation benefits inher-
ent in these cross-industry partnerships. Further detail will be given on insights 
and challenges gleaned from interviewing large and small stakeholders as well as 
practical strategies, such as experimentation with data integration projects, to guide 
the transformation to a systems-thinking industry.
dIsease-sPeCIfIC stUdIes
GastroIntestInal dIsorders – Clinical outcomes studies
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objeCtives: To compare the relative efficacy and safety of golimumab, inflixi-
mab and adalimumab for the treatment of moderate-to-severe ulcerative colitis 
using indirect treatment comparison (ITC) meta-analysis. Methods: A system-
atic literature search identified five randomized controlled trials. Outcomes of 
interest included clinical remission, clinical response, mucosal healing, sustained 
remission/response, serious adverse events (SAEs), and discontinuation due to 
adverse events (DAEs). Data was synthesized using Bayesian indirect treatment 
comparison (ITC) meta-analysis. The analysis incorporated advanced intention-to-
treat with baseline priors to account for the alternative design of the golimumab 
trial. Results: After the induction phase, each treatment had significantly 
greater efficacy than placebo all endpoints, with the exception of adalimumab 
for mucosal healing. No statistical differences were observed between golimumab 
and infliximab. Adalimumab had significantly lower efficacy measures compared 
to infliximab for clinical remission (odds ratio [OR] 0.42, 95% credible interval 
[CrI] 0.17-0.97), clinical response (OR 0.45, 95% CrI 0.23-0.89), and mucosal healing 
(OR 0.46, 95% CrI 0.25-0.84) after the induction period. During the maintenance 
phase, each biologic agent exhibited significantly greater efficacy compared to 
placebo for clinical remission, clinical response, and mucosal healing. Golimumab 
100mg was significantly better than adalimumab for clinical response (OR 1.80, 
95% CrI 1.01-3.21) and mucosal healing at 54 weeks (OR 1.88, 95% CrI 1.01-3.49). No 
statistical differences were observed between adalimumab and infliximab. Both 
golimumab 100mg and infliximab were significantly better than adalimumab in 
terms of sustained clinical response (OR 2.40, 95% CrI 1.17-4.86 and OR 1.93, 95% CrI 
1.04-4.06), respectively. For SAEs, there were no statistical differences between any 
of the biologics and placebo. Although all biologics were generally safe, golimumab 
100mg had statistically significantly higher DAEs when compared to adalimumab 
(OR 2.09, 95% CrI 1.07-4.17). ConClusions: In the context of ITC meta-analysis, 
both golimumab and infliximab appear to demonstrate superior efficacy-safety 
profiles compared with adalimumab.
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objeCtives: Over 500,000 cholecystectomies are performed in the U.S. annually. 
The incidence of surgical site infection (SSI) is higher after open compared to 
laparoscopic cholecystectomy, but other procedural risk factors for SSI have not 
been well established. We investigated operative risk factors for SSI following 
cholecystectomy in a large cohort of privately insured patients. Methods: We 
performed a retrospective cohort study of persons aged 18–64 years with ICD-
9-CM procedure or CPT-4 codes for cholecystectomy from 1/1/2004–12/31/2010 
using commercial insurer claims data. Complex procedures and patients (e.g., 
cancer, end-stage renal disease) were excluded. SSIs occurring within 90 days 
after cholecystectomy were identified by ICD-9-CM diagnosis codes. Procedures 
in which SSI or septicemia was coded ≤ 30 days before surgery were also excluded. 
Multivariable logistic regression was used to determine independent risk factors 
for SSI, controlling for age. Results: A total of 113,138 cholecystectomy proce-
dures were identified; 76% were performed in females and the median age was 
43 years (range 18–64). A total of 833 (0.74%) SSIs occurred; the SSI incidence 
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objeCtives: Previous studies have shown that the majority of Medicare patients 
with HCV are under age 65. This study examines how patient characteristics and 
cost differ between Medicare patient age groups. Methods: An analysis of HCV 
patients was conducted using the 2010-2011 Centers for Medicare and Medicaid 
Services Parts A and B fee-for-service claims. Patients with an HCV ICD-9 code 
and 6 months of follow-up were included. Patient characteristics, resource utili-
zation and 6-month costs were compared between patients age< 65 and age≥ 65. 
The impact of age on medical costs adjusting for demographics, reason for 
entitlement(OREC), Medicaid status, and overall health status (measured by CCI) 
was assessed using generalized linear models fit with a gamma distribution and log 
link function. Results: 16,417 HCV patients with complete data were identified. 
Patients under 65 (n= 11,286) were more likely to have an OREC of disability (89%), 
while patients 65+ OREC was primarily due to old age and survivors insurance (80%). 
ESRD accounted for 8.8% of patients age< 65 and 1.7% aged 65+. Medicaid dual-
eligibility was twice as common among younger patients (38.0% vs. 66.8%, p< 0.01). 
Younger patients had a higher prevalence of alcoholism (35.6% vs. 30.6%, p< 0.01) 
and drug abuse (43.3% vs. 12.2%, p< 0.01), comorbidities that are also risk factors for 
HCV. Yet overall health, as measured by CCI, was higher for younger patients (1.82 
vs. 2.51, p< 0.01). Younger patients had more hospitalizations (0.48 vs 0.33, p< 0.01) 
and emergency department visits (2.04 vs. 1.77, p< 0.01). 6-month medical costs 
for patients age< 65 were $1,285 higher than those 65+ (p= 0.01). After adjusting 
for OREC, HCV-related comorbidities, CCI, demographics and Medicaid status, age 
was no longer associated with cost. ConClusions: Medicare HCV patients under 
65 are more expensive to treat. However, this appears to be due to higher rates of 
disability, ESRD and comorbidities, rather than age itself.
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objeCtives: To study cost of illness (COI) by calculating direct and indirect cost 
in the patients with gastrointestinal and liver disease from societal perspec-
tive. Methods: Study was conducted in general medicine ward of government 
tertiary care hospital, north India by including inpatients diagnosed with gastro-
intestinal and liver disorders. In terms of time perspective prevalence approach 
was used to study COI. Direct cost was estimated using admission fee, cost of bed, 
diet charge, cost of medications and diagnostic tests/surgical procedures. Indirect 
cost was estimated using loss of wages, travelling cost, food cost, and cost of bed 
for attendant/s of patient due to hospital stay. Estimated costs were converted to 
purchasing power parity dolor (PPP$) for cross country comparison. To estimate the 
productivity loss, human capital approach was used with assumption that income 
reflects productivity. Results: A total 202 patients (83% males) were included in 
the study. Most prevalent disorder includes alcoholic liver disease (32.5%) and most 
common class of drug prescribed was proton pump inhibitor (94%). Majority of the 
patients (53%) with these diseases has hospital stay of 1 to 7 days. The total direct 
costs and indirect cost of disease for study patients were PPP$ 23518 and PPP$ 30187 
respectively. Direct and indirect cost of disease for each patient was PPP$ 231 and 
PPP$ 277 respectively. The cost of medication (17.8%) and loss of wages (43.9%) 
contributes major component of direct and indirect cost respectively. Total cost for 
males (PPP$ 276.0±145) is significantly higher (P < 0.05) than the total cost for females 
(PPP$ 232.6±146.6). Mean direct and indirect costs incurred by female patients were 
significant less than that of male patients. ConClusions: Cost of medication and 
loss of wages of patients contributes major component of COI. Increasing the num-
ber of day of hospital stay leads to higher cost of burden.
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objeCtives: The aim of the study is to estimate the cost of Hepatitis C in Turkey 
through reaching consensus on the current clinical practice, resource use and 
the course of treatment. Methods: This study uses the Delphi method to reach 
experts’ consensus on the clinical practices currently being used in Turkey. Delphi 
method has been widely used in medical areas where empirical data is scarce. 
The survey developed for this study includes questions to understand the clinical 
resource use in order to calculate the associated costs. According to the literature, 
the panelists’ answers are unlikely to change after the second iteration. Similar 
to theory, a two-iteration panel was needed to reach a consensus in practice. The 
consensus is then used to calculate the cost of chronic hepatitis C, compensated 
cirrhosis, decompensated cirrhosis, hepatocarcinoma and liver transplant health 
states from the payer’s perspective. Results: The Delphi panel included gastroen-
terologists, infectious diseases specialists and a gastroenterologist with transplan-
tation experience. According to panel consensus, among all of the patients that an 
expert follows, the rate of patients who need hepatitis C treatment (regardless of 
diagnosis) is 1% for gastroenterologists and 20% for infectious diseases specialists. 
ended and open ended multi-country questionnaire was designed to collect data 
from 715 participants (186 Barbers and 529 Clients). Blood samples were withdrawn 
after obtaining an informed consent and were tested for HBV and HCV markers 
by Chromatography, enzyme-lined immunosorbent assay (ELISA) and polymerase 
chain reaction (PCR). Results: The mean age was 28.47±9.7 years in both groups 
of Barbers (n-186) and Clients (n= 529). Among both groups, the sero-prevalence 
of HBV and HCV was 5.7% and 14.4%, respectively. Clients knew about hepatitis 
B and C viruses while barbers were not quite aware. The knowledge about the 
route of transmission was poor among barbers and good among clients. Half of 
the respondents in both groups knew about hepatitis B vaccination and only 15% 
were vaccinated. Sixty percent of the barbers claimed disinfecting the instruments 
between clients and (88.9%) claimed using of new blades. During actual obser-
vation of practices, only 28% disinfected instruments between clients and 62% 
used new blades for each client. ConClusions: There is some awareness among 
barbers and clients about hepatitis B and C viruses but poor knowledge about the 
mode of transmission. This warrants conducting health education campaigns 
to increase awareness about these two blood borne viruses and the risk factors 
associated with their transmission particularly at barbers’ shop and to implement 
interventions to prevent spreading Hepatitis.
GastroIntestInal dIsorders – Cost studies
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objeCtives: Reduction in operative time has been shown to offer significant 
clinical benefits in many procedures including hernia repair surgeries. Ethicon 
Securestrap™ Open, a new mechanical absorbable strap fixation device, takes 
significantly shorter time compared to hand-sutured fixation of IPOM mesh in 
open ventral hernia surgery. This analysis assesses the potential economic value 
of reduction in operative time with mechanical fixation compared to suture fixa-
tion. Methods: An economic model was developed to evaluate the budget impact 
to hospitals of adopting Ethicon Securestrap™ Open repair of ventral hernia. A 
reduction in mean fixation time comparing suture to mechanical fixation was 
included based on a preclinical study that demonstrated about 89% reduction. 
Related benefits in terms of risk of surgical site infections, owing to shorter oper-
ative duration were included based on the literature. Costs of the mechanical 
fixation device and suture supplies, OR time, anesthesia time, and potentially 
avoided surgical site infections were considered in the economic model. Results: 
Based on the model inputs, an overall potential saving of $259,604 (43%) was 
estimated for 100 fixations if they were done using Ethicon Securestrap™ Open 
versus sutures. Although the use of Ethicon Securestrap™ Open added $50,000 in 
supplies costs, this was completely offset by potential savings in OR time costs 
($186,570), potential reduction in avoided surgical site infection or seroma costs 
due to shorter operating room time ($104,210), and in anesthesia costs ($14,324). 
Use of Ethicon Securestrap™ Open was also estimated to be potentially freeing 
up a total of about 58 hours in OR time per 100 conversions. ConClusions: This 
analysis represents the first economic evaluation of Ethicon Securestrap™ Open 
use in open ventral hernia surgery. Adoption of Ethicon Securestrap™ Open fixa-
tion device would likely result in significant savings for hospitals, driven by shorter 
procedure time and its related clinical benefits.
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objeCtives: Hemostasis after liver resection may be difficult to achieve and there 
is thus an increased focus on reducing blood loss and resource use with hemo-
static products. This study estimated the cost impact of a novel fibrin sealant 
patch (i.e., EVARREST) vs. standard of care (SoC) for bleeding control in hepatic 
resection. Methods: An economic analysis quantified 30-day cost impact of 
EVARREST vs. SoC from a German hospital perspective. This analysis used data 
from a randomized trial, which included aggregated resource use reported within 
30 days. Resources included initial treatment and re-treatment, operating time, 
hospitalization, transfusions, and ventilator. SoC was composed of manual com-
pression with a small percentage using hemostats. The primary analysis included 
resources clinically related to the significant hemostasis benefit of EVARREST vs. 
SoC (i.e., initial treatment and re-treatment with hemostasis methods, operating 
time, transfusions, and blood units). A secondary analysis included all resources 
evaluated in the primary analysis with the addition of hospital stay, proportion of 
patients using ventilator, and mean ventilator hours. A projected global price for 
EVARREST was used based on average USD to Euro exchange rate over the last 10 
years. Published data on German costs were applied to resource use. Sensitivity 
analyses were conducted on several variables including EVARREST costs (€ 472 to 
€ 735) for available sizes. Results: The primary analysis predicted that EVARREST 
acquisition cost is offset with cost impact reduced to € 82 per patient vs. SoC (sensi-
tivity range: -€ 86 to € 225). Secondary analyses predicted further resource reduction 
with EVARREST leading to cost-savings (i.e., -€ 458 per patient). Operating time and 
hospital stay were important analysis drivers. ConClusions: This analysis sug-
gests that EVARREST may result in cost savings, in addition to meeting an impor-
tant unmet need for controlling bleeding in hepatic surgery. Further study in more 
patients may be required to confirm findings.
